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Abstract
Methylation of N6 adenosine (m6A) is known to be important for diverse biological processes including gene expression
control, translation of protein, and messenger RNA (mRNA) splicing. However, its role in the development of human
cancers is poorly understood. By analyzing datasets from the Cancer Genome Atlas Research Network (TCGA) acute
myeloid leukemia (AML) study, we discover that mutations and/or copy number variations of m6A regulatory genes are
strongly associated with the presence of TP53 mutations in AML patients. Further, our analyses reveal that alterations in
m6A regulatory genes confer a worse survival in AML. Our work indicates that genetic alterations of m6A regulatory genes
may cooperate with TP53 and/or its regulator/downstream targets in the pathogenesis and/or maintenance of AML.
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To the editor
Methylation of N6 adenosine (m6A) is the most abun-
dant form of messenger RNA (mRNA) modification in
eukaryotes [1]. It is known to play crucial roles in the
regulation of gene expression, protein translation, and
splicing in normal biology [1, 2]. m6A regulatory en-
zymes consist of “writers” METTL3 and METTL14,
“readers” YTHDF1 and YTHDF2, and “erasers” FTO
and ALKBH5 [1]. m6A perturbation mediated via knock-
down or knockout of these enzymes can cause cell
death, decreased cell proliferation, impaired self-renewal
capacity, and developmental defects [1]. For example,
ablation of METTL3 perturbs embryonic stem cell dif-
ferentiation [1]. Depletion of FTO and ALKBH5 leads to
obesity and impairment of spermatogenesis, respectively
[1]. Silencing of m6A methyltransferase can result in
modulation of the TP53 signaling pathway of relevance
to tumorigenesis [2]. More recently, overexpression of
FTO has been shown to promote leukemogenesis [3]. It
is therefore surprising that genetic alterations affecting
m6A regulatory genes have not been explored in human
cancers, including leukemia. Hence, there is a compel-
ling reason to determine whether mutations, deletions,
and amplifications of m6A regulatory genes are enriched
in leukemia subtypes. Clinicopathological associations
including patient survival have not previously been
reported.
Here, we curate mutations, including point mutations,
deep deletions, and amplifications of the best character-
ized m6A regulatory genes, METTL3, METTL14,
YTHDF1, YTHDF2, FTO, and ALKBH5. Deep deletions
are possibly homozygous deletions as measured using
the Genomic Identification of Significant Targets in
Cancer algorithm (GISTIC). Four distinct types of
hematological malignancies were sequenced by the
Cancer Genome Atlas Research (TCGA) Network: acute
myeloid leukemia (AML), multiple myeloma (MM),
acute lymphoblastic leukemia (ALL), and chronic
lymphocytic leukemia (CLL), and genetic data has been
made available via cBioPortal [4]. Mutations of m6A
regulatory genes were found in 2.6% (5/191) of AML,
2.4% (5/205) of MM, 1.0% (1/106) of ALL, and 0% (0/
666) of CLL (Additional file 1: Figure S1a). For AML, we
further identified variation in gene copy number in
10.5% (20/191) of patients (Additional file 2: Table S1).
There was a comparable frequency of copy number loss
measured as shallow deletion (possibly heterozygous
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deletion) using GISTIC (n = 19) and copy number gain
(n = 13) of m6A regulatory genes (Additional file 1:
Figure S1b). Among these, copy number loss of ALKBH5
is the most frequent in this AML cohort (12/191, 6.3%).
Notably, 4.7% (9/191) of AML patients had concomitant
copy number gain or loss of more than one m6A regula-
tory gene (Additional file 2: Table S1). In four of these
nine cases, a copy number gain of an m6A writer was
detected concomitantly with a shallow/deep deletion of
an m6A eraser (Additional file 2: Table S1), indicating a
potential synergistic alteration of m6A regulatory en-
zymes that may lead to increased levels of RNA m6A
modification. Shallow deletions of METTL14, FTO, and
ALLBH5 were significantly associated with reduced
mRNA expression of these genes (Additional file 3:
Figure S2). Copy number gain of METTL14 was sig-
nificantly associated with an increase in its expression
(Additional file 3: Figure S2). Thus, shallow deletion
and copy number gain may result in the reduced and
increased expression of m6A regulatory genes, respectively.
We determined whether mutations and copy number
variations (CNVs) of m6A regulatory genes are associ-
ated with clinicopathological and molecular features of
AML. Mutations and/or CNVs of METTL3, METTL14,
YTHDF1, YTHDF2, FTO, and ALKBH5 as a group were
significantly associated with poorer cytogenetic risk in
AML (P < 0.0001, Table 1). Additionally, we observed a
marked increased in TP53 mutations (P < 0.0001, Table 1)
but a significant lack of NPM1 and FLT3 mutations
(P < 0.005, Table 1) in AML patients harboring genetic
alterations of m6A regulatory genes. These clinicopatho-
logical and molecular features were also associated with
CNVs of m6A regulatory genes alone (Table 1). However,
they were not associated with mutations of m6A regula-
tory genes alone (Table 1), which may be due to the small
number of cases with mutations (n = 5).
We further determined whether shallow/deep deletion of
ALKBH5 is associated with the clinicopathological and mo-
lecular features. Consistent with our findings in m6A regu-
latory genes overall, shallow/deep deletion of ALKBH5 was
significantly associated with poorer cytogenetic risk and the
presence of TP53 mutation in this AML cohort (P < 0.0001,
Additional file 4: Table S2). NPM1 and FLT3 mutations
were absent in AML patients with shallow/deep deletion of
ALKBH5 (Additional file 4: Table S2).
We performed Kaplan-Meier analysis to investigate the
impact of genetic alterations in m6A regulatory genes on
overall (OS) and event-free survival (EFS) in patients with
AML. As a group, patients with a mutation of any of the
genes encoding m6A regulatory enzymes had a worse OS
(P = 0.007) and EFS (P < 0.0001, Fig. 1a). Inferior OS and
EFS were also evident in patients who had mutations and/
or CNVs of these genes (Fig. 1b) and in those with shal-
low/deep deletion of ALKBH5 (Fig. 1c).
Of all clinicopathological and molecular features con-
sidered for this de novo AML cohort [5], older age
(>60 years), white blood cell count > median (15,200 per
mm3), unfavorable cytogenetic risk, and DNMT3A and
TP53 mutations were significantly associated with infer-
ior OS and/or EFS in univariate analyses (Additional file 5:
Figure S3 and Additional file 6: Figure S4). We therefore ex-
amined the impact of m6A regulatory gene mutations and/
or CNVs on the outcome of AML patients with poor risk
genotypes. Alterations of m6A regulatory genes as a group
were associated with inferior OS and EFS in patients regard-
less of age (Additional file 7: Figure S5). These genetic alter-
ations did not confer a worse OS or EFS in patients with
unfavorable cytogenetic risk, white blood cell count > me-
dian, or DNMT3Amutations (Additional file 8: Figure S6).
We further determined the survival of AML patients
based on whether they exhibited combined TP53 muta-
tions and genetic alterations of m6A regulatory genes.
Almost all patients with mutated TP53 (93.6%, Table 1)
had ≥1 genetic alteration(s) of m6A regulatory gene(s).
This group of patients had worse OS and EFS than pa-
tients who did not have any of these genetic alterations
(Additional file 9: Figure S7a). There is a non-significant
trend in patients with wild-type TP53 in combination
with genetic alterations of m6A regulatory genes to ex-
hibit inferior EFS compared to patients without genetic
alterations of these genes (Additional file 9: Figure S7a).
Because mutations, deletions, amplifications, and/or
CNVs of m6A regulatory genes were relatively confined
to patients with wild-type FLT3 and NPM1 (95.6%,
Table 1), we determined whether these genetic alter-
ations impact OS and EFS stratified by FLT3 or NPM1
mutation status. Inferior OS and EFS were observed in
patients with wild-type FLT3 who had ≥1 genetic
alteration(s) of m6A regulatory gene(s) (P < 0.0001,
Additional file 9: Figure S7b). Notably, these patients
also had worse OS (P < 0.041) and EFS (P < 0.042)
compared to patients who had mutant FLT3 but no gen-
etic alteration of m6A regulatory genes (Additional file 9:
Figure S7b). Genetic alterations of m6A regulatory genes
as a group were also significantly associated with a worse
OS and EFS in patients with wild-type NPM1 (P < 0.0001,
Additional file 9: Figure S7c). Integration of molecular
analyses of m6A regulatory genes may be useful to deter-
mine a poorer outcome in AML patients who have neither
been classified as “poor risk” due to the presence of FLT3
mutations [6, 7] nor better outcome conferred by NPM1
mutations [8], particularly within a group of TP53 wild-
type patients.
In a multivariate Cox proportional hazard model that
includes variables associated with poorer survival, gen-
etic alterations of m6A regulatory genes as a group were
not an independent prognostic factor for OS (Fig. 1d).
However, genetic alterations of m6A regulatory genes
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did independently predict poorer OS (hazard ratio =
2.073; 95% CI, 1.13–3.80; P = 0.018) when TP53 muta-
tion was excluded from the model (Fig. 1d). Similar re-
sults were observed in multivariate analyses to predict
EFS (Fig. 1d). Our results support a strong association
between genetic alterations of m6A regulatory genes and
TP53 mutation. The fact that one is confounding the
other in predicting patients’ outcome suggests that both
may be complementary in the pathogenesis and/or
maintenance of AML.
Identification of novel biomarkers and molecular tar-
gets to guide the development of anti-leukemic therapies
remains a major challenge. Particularly for AML, the
molecular markers to define subtypes and prognosis are
under continuous refinement [7, 9]. Given that m6A
modification to RNA has broad physiological functions,
its impairment may be associated with the development
and progression of diverse cancers, including leukemia.
The current WHO classification highlights epigenetic
modifiers as being mutated early during the clonal
Fig. 1 Kaplan-Meier curves for overall and event-free survival of TCGA AML patients by the presence and absence of a mutation of m6A regulatory
genes, b mutation and/or copy number variation (CNV) of m6A regulatory genes, and c deletion/copy number loss of the ALKBH5 gene encoding an
important m6A “eraser.” Mutations include point mutation, deep deletion, and amplification. Log-rank test was used to determine significance.
+, censored data. d Multivariate analysis for overall and event-free survival in TCGA AML patients
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evolution of AML [9]. Novel genetic subgroups now in-
clude mutation in genes that encode splicing regulators,
TP53, and other epigenetic modifiers [9].
Our present study is the first to determine the clinico-
pathological associations and impact of genetic alter-
ations affecting m6A regulatory genes in AML. We
found a striking association between genetic alterations
of these genes as a group and TP53 mutations (Table 1).
Importantly, genetic alterations of m6A regulatory genes
are associated with inferior outcome in AML patients,
although this may be confounded by the adverse impact
of TP53 mutations on survival [10] (Additional files 6:
Figure S4 and 9: Figure S7). It has been established that
loss of the m6A methyltransferase, METTL3, resulted in
alternative splicing and gene expression changes of >20
genes involved in the TP53 signaling pathway includ-
ing MDM2, MDM4, and P21 in a human liver cancer
cell line [2]. It is plausible that genetic alterations of
m6A modifiers, TP53, and/or its regulator/down-
stream targets contribute in complementary pathways
to the pathogenesis and/or maintenance of AML. Fur-
ther studies in larger AML cohorts would assist in
confirming our findings and spur future research into
the functional role of m6A RNA modification in AML
and its link to tumorigenesis pathways, especially
TP53 signaling.
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